Patents Assigned to CV Therapeutics, Inc.
-
Patent number: 7713946Abstract: Disclosed are novel compounds a compound of Formula I that are partial and full A1 adenosine receptor agonists, useful for treating various disease states, in particular dyslipidemia, diabetes, decreased insulin sensitivity, Polycystic Ovarian Syndrome, Stein-Leventhal syndrome, and obesity.Type: GrantFiled: December 18, 2006Date of Patent: May 11, 2010Assignee: CV Therapeutics, Inc.Inventors: Arvinder Dhalla, Elfatih Elzein, Prabha Ibrahim, Venkata Palle, Vaibhav Varkhedkar, Jeff Zablocki
-
Patent number: 7696181Abstract: Disclosed are novel compounds that are partial and full A1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, myocardial infarction and hyperlipidemia. The structure of the compounds is given by Formula (I): wherein R1, R2, R3, R4, R5, X, Y, Z, and T are as described herein.Type: GrantFiled: August 24, 2006Date of Patent: April 13, 2010Assignee: CV Therapeutics, Inc.Inventors: Prabha Ibrahim, Elfatih Elzein, Kevin Shenk, Robert Jiang, Jeff Zablocki, Xiaofen Li, Christopher Morrison, Thao Perry, Dengming Xiao
-
Patent number: 7582617Abstract: The present invention provides a method for using the partial adenosine A2A receptor agonists having the following structure in myocardiological perfusion imaging.Type: GrantFiled: March 2, 2005Date of Patent: September 1, 2009Assignee: CV Therapeutics, Inc.Inventors: Luiz Belardinelli, Brent K. Blackburn, Zhenhai Gao
-
Patent number: 7553823Abstract: 2-adenosine C-pyrazole compounds having formula (a) and methods for using the compounds as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.Type: GrantFiled: September 15, 2006Date of Patent: June 30, 2009Assignee: CV Therapeutics, Inc.Inventors: Jeff A. Zablocki, Elfatih O. Elzein, Venkata P. Palle
-
Patent number: 7521554Abstract: Disclosed are processes for the synthesis of novel compounds that are A2B adenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea.Type: GrantFiled: August 22, 2006Date of Patent: April 21, 2009Assignee: CV Therapeutics, Inc.Inventors: Elfatih Elzein, Rao Kalla, Tim Marquart, Jeff Zablocki, Xiaofen Li
-
Patent number: 7517888Abstract: Disclosed are A1 adenosine receptor antagonists having the general formula The compounds are useful for treating various disease states, in particular disease states for which diuretic treatment is appropriate.Type: GrantFiled: April 28, 2005Date of Patent: April 14, 2009Assignee: CV Therapeutics, Inc.Inventor: Gloria Cristalli
-
Patent number: 7514417Abstract: Disclosed are novel compounds that are partial and full A1 adenosine receptor agonists having the structure of Formula I: which are useful for treating various disease states, in particular tachycardia and atrial flutter, angina, and myocardial infarction.Type: GrantFiled: May 19, 2006Date of Patent: April 7, 2009Assignee: CV Therapeutics, Inc.Inventors: Elfatih Elzein, Rao Kalla, Thao Perry, Jeff Zablocki, Xiaofen Li
-
Patent number: 7488720Abstract: Disclosed are novel compounds that are A1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, diseases related to release of nonesterified fatty acids, and myocardial infarction.Type: GrantFiled: October 11, 2006Date of Patent: February 10, 2009Assignee: CV Therapeutics, Inc.Inventors: Elfatih Elzein, Xiaofen Li, Jeff Zablocki
-
Patent number: 7479485Abstract: Methods are provided for treating arrhythmia in a manner that minimizes undesirable side effects, comprising administration of a therapeutically effective minimal dose of an A1 adenosine receptor agonist with a therapeutically effective minimal dose of a beta blocker, calcium channel blocker, or a cardiac glycoside.Type: GrantFiled: October 28, 2005Date of Patent: January 20, 2009Assignee: CV Therapeutics, Inc.Inventors: Luiz Belardinelli, Arvinder Dhalla
-
Patent number: 7452889Abstract: Disclosed are novel substituted heterocyclic derivatives having the structure of Formula I: The compounds are useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, diabetes, and myocardial infarction.Type: GrantFiled: August 27, 2007Date of Patent: November 18, 2008Assignee: CV Therapeutics, Inc.Inventors: Elfatih Elzein, Prabha Ibrahim, Venkata Palle, Kenneth Rehder, Jeff Zablocki
-
Patent number: 7449473Abstract: Disclosed are novel compounds that are A2B adenosine receptor antagonists having the following structure: wherein R1 and R2 are independently chosen from hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl, and R4 is an optionally substituted heteroaryl moiety. The compounds of the invention are useful for treating various disease states, including asthma, chronic obstructive pulmonary disorder, pulmonary inflammation, emphysema, diabetic disorders, inflammatory gastrointestinal tract disorders, immunological/inflammatory disorders, cardiovascular diseases, neurological disorders, and diseases related to angiogenesis.Type: GrantFiled: October 26, 2004Date of Patent: November 11, 2008Assignee: CV Therapeutics, Inc.Inventors: Rao Kalla, Elfatih Elzein, Tim Marquart, Thao Perry, Xiaofen Li, Jeff Zablocki
-
Publication number: 20080267861Abstract: This invention relates to methods for performing myocardial perfusion imaging for diagnosing and characterizing coronary artery disease using an intravenous (IV) bolus injection of regadenoson while the patient is undergoing sub-maximal exercise.Type: ApplicationFiled: January 3, 2008Publication date: October 30, 2008Applicant: CV THERAPEUTICS, INC.Inventors: Hsiao D. Lieu, Gregory Thomas
-
Patent number: 7432276Abstract: The present invention provides compounds useful for increasing cellular ATP binding cassette transporter ABCA1 production in mammals, and to methods of using such compounds in the treatment of coronary artery diseases, dyslipidiemias and metabolic syndrome. The invention also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.Type: GrantFiled: December 27, 2006Date of Patent: October 7, 2008Assignee: CV Therapeutics, Inc.Inventors: Matthew Abelman, Robert Jiang, Jeff Zablocki, Dmitry Koltun, Melanie Boze
-
Patent number: 7423045Abstract: The present invention provides compounds useful for increasing cellular ATP binding cassette transporter ABCA1 production in mammals, and to methods of using such compounds in the treatment of coronary artery diseases, dyslipidiemias and metabolic syndrome. The invention also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.Type: GrantFiled: June 28, 2006Date of Patent: September 9, 2008Assignee: CV Therapeutics, Inc.Inventors: Matthew Abelman, Robert Jiang, Jeff Zablocki, Dmitry Koltun
-
Patent number: 7419709Abstract: Coatings are provided in which surfaces may be activated by covalently bonding a silane derivative to the metal surface, covalently bonding a lactone polymer to the silane derivative by in situ ring opening polymerization, and depositing at least one layer of a polyester on the bonded lactone. Biologically active agents may be deposited with the polyester layers. Such coated surfaces may be useful in medical devices, in particular stents.Type: GrantFiled: November 28, 2006Date of Patent: September 2, 2008Assignee: CV Therapeutics, Inc.Inventors: Frantisek Rypacek, Monika Lapcikova, Ludka Machova
-
Patent number: 7407960Abstract: Disclosed are novel heterocyclic compounds having the structure which are useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction. The compounds are also useful in the treatment of diabetes.Type: GrantFiled: September 7, 2006Date of Patent: August 5, 2008Assignee: CV Therapeutics, Inc.Inventors: Elfatih Elzein, Dmitry Koltun, Jeff Zablocki
-
Publication number: 20080170990Abstract: The present application discloses methods for myocardial imaging in human patients having a history of pulmonary disease such as asthma, bronchospasm, chronic obstructive pulmonary disease, pulmonary fibrosis, pulmonary inflammation, or pulmonary hypertension, comprising administrating doses of one or more A2A adenosine receptor agonists to a mammal undergoing myocardial imaging and detecting and/or diagnosing myocardial dysfunction.Type: ApplicationFiled: September 28, 2007Publication date: July 17, 2008Applicant: CV THERAPEUTICS, INC.Inventors: Hsiao D. Lieu, Brent Blackburn, Luiz Belardinelli
-
Patent number: 7381714Abstract: Disclosed are novel compounds that are partial and full A1 adenosine receptor agonists having the structure of Formula I: which are useful for treating various disease states, in particular tachycardia and atrial flutter, angina, and myocardial infarction.Type: GrantFiled: May 19, 2006Date of Patent: June 3, 2008Assignee: CV Therapeutics, Inc.Inventors: Elfatih Elzein, Rao Kalla, Thao Perry, Jeff Zablocki, Xiaofen Li
-
Patent number: 7364768Abstract: Coatings are provided in which surfaces may be activated by covalently bonding a silane derivative to the metal surface, covalently bonding a lactone polymer to the silane derivative by in situ ring opening polymerization, and depositing at least one layer of a polyester on the bonded lactone. Biologically active agents may be deposited with the polyester layers. Such coated surfaces may be useful in medical devices, in particular stents.Type: GrantFiled: November 28, 2006Date of Patent: April 29, 2008Assignee: CV Therapeutics, Inc.Inventors: Frantisek Rypacek, Monika Lapcikova, Ludka Machova
-
Patent number: 7351535Abstract: The present invention relates to novel ABC1 polypeptides and nucleic acid molecules encoding the same. The invention also relates to recombinant vectors, host cells, and compositions comprising ABC1 polynucleotides, as well as to methods for producing ABC1 polypeptides. The invention also relates to antibodies that bind specifically to ABC1 polypeptides. In addition, the invention relates to methods for increasing cholesterol efflux as well as to methods for increasing ABC1 expression and activity. The present invention further relates to methods for identifying compounds that modulate the expression of ABC1 and methods for detecting the comparative level of ABC1 polypeptides and polynucleotides in a mammalian subject. The present invention also provides kits and compositions suitable for screening compounds to determine the ABC1 expression modulating activity of the compound, as well as kits and compositions suitable to determine whether a compound modulates ABC1-dependent cholesterol efflux.Type: GrantFiled: August 18, 2004Date of Patent: April 1, 2008Assignee: CV Therapeutics, Inc.Inventors: Richard M Lawn, David Wade, Michael Garvin